Non-invasive detection of bladder cancer through the analysis of driver gene 1 mutations and aneuploidy 2 3

[1]  K. Kinzler,et al.  Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder , 2017, Virchows Archiv.

[2]  Rajesh C. Dash,et al.  Anticipatory Positive Urine Tests for Bladder Cancer , 2017, Annals of Surgical Oncology.

[3]  K. Kinzler,et al.  High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma , 2016, Virchows Archiv.

[4]  C. VandenBussche,et al.  The cytomorphological features of low‐grade urothelial neoplasms vary by specimen type , 2016, Cancer cytopathology.

[5]  K. Kinzler,et al.  Diagnostic potential of tumor DNA from ovarian cyst fluid , 2016, eLife.

[6]  K. Kinzler,et al.  Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. , 2016, Human pathology.

[7]  M. Quek,et al.  The Paris System for Reporting Urinary Cytology: The Quest to Develop a Standardized Terminology , 2016, Acta Cytologica.

[8]  G. Netto,et al.  Emerging Bladder Cancer Biomarkers and Targets of Therapy. , 2016, The Urologic clinics of North America.

[9]  D. Dietrich,et al.  Epigenetic biomarkers in the blood of patients with urological malignancies , 2015, Expert review of molecular diagnostics.

[10]  F. Brimo,et al.  Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. , 2015, Urologic oncology.

[11]  C. Liu,et al.  TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR , 2014, Oncotarget.

[12]  Navneeta Bansal,et al.  Low- and high-grade bladder cancer appraisal via serum-based proteomics approach. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[13]  G. Kristiansen,et al.  Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies , 2014, Critical reviews in clinical laboratory sciences.

[14]  P. Rothberg,et al.  Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma , 2014, Modern Pathology.

[15]  M. Knowles,et al.  Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. , 2014, European urology.

[16]  T. Ørntoft,et al.  Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. , 2014, European urology.

[17]  K. Kinzler,et al.  TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. , 2013, Cancer research.

[18]  G. Netto.  Clinical Applications of Recent Molecular Advances in Urologic Malignancies: No Longer Chasing a “Mirage”? , 2013, Advances in anatomic pathology.

[19]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[20]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[21]  D. Schadendorf,et al.  TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[22]  S. Goodison,et al.  A Multi-Analyte Assay for the Non-Invasive Detection of Bladder Cancer , 2012, PloS one.

[23]  K. Kinzler,et al.  FAST-SeqS: A Simple and Efficient Method for the Detection of Aneuploidy by Massively Parallel Sequencing , 2012, PloS one.

[24]  P. Guldberg,et al.  Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events , 2011, International journal of cancer.

[25]  Wen-Jeng Wu,et al.  Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine. , 2010, Urologic oncology.

[26]  T. Furuya,et al.  9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology. , 2009, Human pathology.

[27]  Robert E. Brown,et al.  Field effect in cancer-an update. , 2009, Annals of clinical and laboratory science.

[28]  T. Hajdinjak.  UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. , 2008, Urologic oncology.

[29]  C. Cordon-Cardo,et al.  Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. , 2007, The Journal of clinical investigation.

[30]  S. Johansson,et al.  Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. , 2006, The Journal of urology.

[31]  Xue-Ru Wu.  Urothelial tumorigenesis: a tale of divergent pathways , 2005, Nature Reviews Cancer.

[32]  A. Feller,et al.  Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. , 2003, International journal of oncology.

[33]  J. Jones,et al.  Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. , 2003, The Journal of urology.

[34]  D. Neal,et al.  A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. , 2000, The Journal of urology.

[35]  O. Yoshida,et al.  Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. , 1998, Cancer research.

[36]  Y. Fradet,et al.  Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. , 1997, The Canadian journal of urology.

[37]  C. Cordon-Cardo,et al.  Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. , 1995, The Journal of urology.

[38]  C. Cordon-Cardo,et al.  Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. , 1994, The Journal of urology.

[39]  C. Cordon-Cardo,et al.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. , 1993, Journal of the National Cancer Institute.

[40]  Jonathan I. Epstein,et al.  WHO Classification of of Tumours of the Urinary System and Male Genital Organs , 2016 .

[41]  The Cancer Genome Atlas Research Network.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[42]  G. Netto.  Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? , 2012, Nature Reviews Urology.

[43]  G. Nabi,et al.  Diagnosis of urologic malignancies in patients with asymptomatic dipstick hematuria: prospective study with 13 years' follow-up. , 2008, Urology.

[44]  D. Schadendorf,et al.  Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2022 .